2016 Volume 22 Issue 2 Pages 146-151
Background: Adjuvant chemotherapies with oxaliplatin is shown to reduce the recurrence rates of tumors in patients with stage-III colorectal cancer, when the therapies were performed after curative surgical resection. Hepatic sinusoidal obstruction syndrome (SOS) however, might occur in patients receiving oxaliplatinas an adverse effect, and may increase the risk of additional therapies when recurrence and metastasis of the cancer developed. Recently, splenic volume was shown to reflect the severity of SOS through the evaluation comparing histological findings on liver biopsy specimens and imaging findings. Thus, in the present study, the extents of SOS were evaluated through splenic volume in patients with FOLFOX therapy.
Patients & Method: Consecutive 32 patients receiving adjuvant FOLFOX therapy after curative surgical resection for colorectal cancer were enrolled between January 2011 and December 2013. All patients were classified into stage-III or high-risk stage-II. Splenic volumes were measured on CT imaging using SYNAPSE VINCENT v3.0® software for 3 times; before, immediately after and 1 year after the adjuvant chemotherapy.
Results: Splenic volumes were increased in 22 patients (68.7%) immediately after the therapies compared to those before the therapies, and such increase was statistically significant (p=0.0026). Splenic volumes were decreased in these patients at 1 year after the therapies than those immediately after the therapies (p=0.0076). In 11 patients (34.7%), however, such recover of splenic volumes were not observed at 1 tear after the therapies.
Conclusion: Splenic volumes increased immediately after FOLFOX therapy compared to those at baseline, and such increase was observed even at 1 year lattes in a half of these patients. In such patients, complication of SOS should be considered when additional therapies were done for reccurence of the cancer.
